The Board of Directors of BKCB wishes to announce that Bintai Kinden Corporation Berhad ("BKCB") has on 14 August 2020 entered into a Memorandum of Understanding ("MOU") with Nugenerex Immuno-Oncology, a company incorporated in the United States of America ("GENEREX") for the preliminary understanding of arrangement for the collaboration between the Parties in the funding, launching and management of synthetic peptide vaccine for SARS-CoV-2 ("Vaccine") [collectively the "Project"] subject to the terms and conditions of the MOU. The Parties shall later enter into a formal Agreement to further detailed their respective roles and obligations under the Project which is subjected to the results of due diligence at a later stage.